The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients
Primary Purpose
Coronary Heart Disease, Acute Myocardial Infarction
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Tongguan capsule
placebo capsule
Sponsored by
About this trial
This is an interventional prevention trial for Coronary Heart Disease focused on measuring acute coronary syndrome, Tongguan capsule, miRNAs
Eligibility Criteria
Inclusion Criteria:
- In line with the diagnostic criteria for acute coronary syndrome (ACS), coronary angiography confirmed for coronary heart disease (CHD), parallel Percutaneous transluminal coronary angioplasty( PTCA) and/or coronary stent implantation was successful
- Postoperative routine drug treatment
- Traditional Chinese Medicine syndrome differentiation of qi -deficiency and qi -stagnation blood stasis or blood stasis license
- Aged 35 to 75 years old
- Must sign a consent form.
Exclusion Criteria:
- Renal insufficiency, the male serum creatinine > 2.5 mg/dl (> 220 umo/l), women > 2.0 mg/dl (> 175 umo/l)
- With obvious liver disease or Alanine aminotransferase ( ALT), Aspartate aminotransferase ( AST), 3 times higher than normal ceiling
- Serious cardiac insufficiency (EF < 35%)
- Uncontrolled patients with high blood pressure
- Merger or severe valvular heart disease in acute cerebrovascular disease
- Random blood glucose or greater tendency for 13.7 / L diabetes or glycosylated hemoglobin 9.5% or more
- Patients with severe mental illness
- Patients with malignant tumor or life expectancy in less than three years
- Patients with severe hematopoietic system disease
- Refused to sign a consent form, or estimated compliance is poorer, follow-up possibilities claim;
- Pregnancy or ready to pregnant women, nursing mothers;
- Participated in nearly three months, or is in other clinical subjects . -
Sites / Locations
- Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Tongguan capsule
placebo capsule
Arm Description
Tongguan capsule (0.5 g tid. for 6 months)
same volume/day of placebo capsule (0.5 g tid. for 6 months)
Outcomes
Primary Outcome Measures
miRNAs spectrum
Test the expression of microRNAs related to the syndromes after the intervention of Tongguan capsule,preliminarily to investigate the mechanism of the effects of Tongguan capsule, and provide the biological foundation of curative effect of Tongguan capsule.
Secondary Outcome Measures
major adverse cardiac event
frequency of the reported cardiovascular events (defined as cardiogenic death, stroke, recurrent myocardial infarction, readmission on account of deterioration of congestive heart failure or unstable angina, target vessel revascularization)
Renin predicts cardiovascular homeostasis and ventricular remodeling
renin(ng/ml) predicts cardiovascular homeostasis and blood pressure maintenance and plays an important role in ventricular remodeling
Ang II predicts cardiovascular homeostasis and ventricular remodeling
Ang II(pg/ml) predicts cardiovascular homeostasis and blood pressure maintenance and plays an important role in ventricular remodeling
Serum E
Acute coronary syndrome is caused by atherosclerotic plaque instability and rupture. The stability of plaque is closely related to inflammation.Serum E (pmol / L) is an important pathway of various immune and inflammatory regulation, which promotes the development of atherosclerosis and is a risk factor for atherosclerosis.
Inflammatory mediators
Tumor Necrosis factor alpha (ng/L)and Interleukin-6,IL-6 (ng/L) measure of the general situation of patients
Brain Natriuretic Peptide
B-type natriuretic peptide(pg/ml) is a neurohormone synthesized in the cardiac ventricles upon ventricular pressure overload and ventricular dilatation
Echocardiography measure of left ventricular systolic function
Evaluation of left ventricular systolic function by left ventricular ejection fraction( LVEF) (%)
Echocardiography measure of left ventricular diastolic function
Left ventricular end diastolic diameter (LVEDD) (mm )measure of left ventricular diastolic function in patients
New York Heart Association functional classification
I Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. no shortness of breath when walking, climbing stairs etc. II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. III Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest. IV Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
Coronary angiography
Quantitative coronary angiography in the stenosis degree, 25%, 50%, 75%, 90%, 99%, 100%, 1, 2, 4, 6, 8,, 16, 32, and, respectively.
Scoring multiplication will segment coefficients corresponding to the degree of stenosis and the stenosis of total score that is the sum of Gensini score of coronary artery stenosis in the patients.
Seattle Angina Questionnaire score
The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception). (in Units on a Scale).
The traditional Chinese medicine syndrome scale
The traditional Chinese medicine syndrome scale Including the the score of deficiency of qi and score of blood stasis syndrome mainly used to identify patients with traditional Chinese medicine syndrome type
Full Information
NCT ID
NCT02850627
First Posted
July 21, 2016
Last Updated
July 31, 2016
Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
1. Study Identification
Unique Protocol Identification Number
NCT02850627
Brief Title
The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients
Official Title
The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Unknown status
Study Start Date
July 2016 (undefined)
Primary Completion Date
September 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to test the expression of microRNAs related to the syndromes after the intervention of Tongguan capsule,preliminarily to investigate the mechanism of the effects of Tongguan capsule, and provide the biological foundation of curative effect of Tongguan capsule.
Detailed Description
The primary end points is the core of the whole experiment scheme. miRNAs regulate gene expression posttranscriptionally by degrading messenger RNA (mRNA) targets and by blocking their translation Secondary endpoints will include The adverse cardiac clinical events (MACE) in terms of cardiac death,periprocedural myocardial infarction (MI),spontaneous MI and target vessel revascularization(TVR). Related parameters of qi and blood are the material basis of blood conversion and objective performance is used to evaluate the effect on Tongguan capsule on patients with blood stagnation, which can be either interpretation theory of qi deficiency and blood stagnation and mutual transformation between qi and blood can find targets through Tongguan capsule on blood . Routine laboratory tests are used for screening patients basic situation and ensure the safety of the experiment The traditional Chinese medicine syndrome scale Including the the score of deficiency of qi and score of blood stasis syndrome mainly used to identify patients with the traditional Chinese medicine syndrome type Approximately 100 patients in Coronary Heart Disease Patients with Blood Stasis Syndrome undergoing percutaneous coronary intervention will be enrolled and randomized to divided into Qi -stagnation and blood stasis, Qi- deficiency and blood stasis, after the PCI surgery, Qi deficiency and blood stasis group were randomly divided into Tongguan capsule group and the control group, and qi stagnation and blood stasis group, too ,giving patients through Tongguan capsule 3 pills three times a day(1.5g/day), once every three months follow-up, after have been followed up to six months
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Heart Disease, Acute Myocardial Infarction
Keywords
acute coronary syndrome, Tongguan capsule, miRNAs
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Tongguan capsule
Arm Type
Experimental
Arm Description
Tongguan capsule (0.5 g tid. for 6 months)
Arm Title
placebo capsule
Arm Type
Placebo Comparator
Arm Description
same volume/day of placebo capsule (0.5 g tid. for 6 months)
Intervention Type
Drug
Intervention Name(s)
Tongguan capsule
Intervention Description
eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
Intervention Type
Drug
Intervention Name(s)
placebo capsule
Intervention Description
eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
Primary Outcome Measure Information:
Title
miRNAs spectrum
Description
Test the expression of microRNAs related to the syndromes after the intervention of Tongguan capsule,preliminarily to investigate the mechanism of the effects of Tongguan capsule, and provide the biological foundation of curative effect of Tongguan capsule.
Time Frame
six months
Secondary Outcome Measure Information:
Title
major adverse cardiac event
Description
frequency of the reported cardiovascular events (defined as cardiogenic death, stroke, recurrent myocardial infarction, readmission on account of deterioration of congestive heart failure or unstable angina, target vessel revascularization)
Time Frame
six months
Title
Renin predicts cardiovascular homeostasis and ventricular remodeling
Description
renin(ng/ml) predicts cardiovascular homeostasis and blood pressure maintenance and plays an important role in ventricular remodeling
Time Frame
6 months
Title
Ang II predicts cardiovascular homeostasis and ventricular remodeling
Description
Ang II(pg/ml) predicts cardiovascular homeostasis and blood pressure maintenance and plays an important role in ventricular remodeling
Time Frame
6 months
Title
Serum E
Description
Acute coronary syndrome is caused by atherosclerotic plaque instability and rupture. The stability of plaque is closely related to inflammation.Serum E (pmol / L) is an important pathway of various immune and inflammatory regulation, which promotes the development of atherosclerosis and is a risk factor for atherosclerosis.
Time Frame
6 months
Title
Inflammatory mediators
Description
Tumor Necrosis factor alpha (ng/L)and Interleukin-6,IL-6 (ng/L) measure of the general situation of patients
Time Frame
6 months
Title
Brain Natriuretic Peptide
Description
B-type natriuretic peptide(pg/ml) is a neurohormone synthesized in the cardiac ventricles upon ventricular pressure overload and ventricular dilatation
Time Frame
6 months
Title
Echocardiography measure of left ventricular systolic function
Description
Evaluation of left ventricular systolic function by left ventricular ejection fraction( LVEF) (%)
Time Frame
6 months
Title
Echocardiography measure of left ventricular diastolic function
Description
Left ventricular end diastolic diameter (LVEDD) (mm )measure of left ventricular diastolic function in patients
Time Frame
6 months
Title
New York Heart Association functional classification
Description
I Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. no shortness of breath when walking, climbing stairs etc. II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. III Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest. IV Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
Time Frame
6 months
Title
Coronary angiography
Description
Quantitative coronary angiography in the stenosis degree, 25%, 50%, 75%, 90%, 99%, 100%, 1, 2, 4, 6, 8,, 16, 32, and, respectively.
Scoring multiplication will segment coefficients corresponding to the degree of stenosis and the stenosis of total score that is the sum of Gensini score of coronary artery stenosis in the patients.
Time Frame
6 months
Title
Seattle Angina Questionnaire score
Description
The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception). (in Units on a Scale).
Time Frame
6 months
Title
The traditional Chinese medicine syndrome scale
Description
The traditional Chinese medicine syndrome scale Including the the score of deficiency of qi and score of blood stasis syndrome mainly used to identify patients with traditional Chinese medicine syndrome type
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
In line with the diagnostic criteria for acute coronary syndrome (ACS), coronary angiography confirmed for coronary heart disease (CHD), parallel Percutaneous transluminal coronary angioplasty( PTCA) and/or coronary stent implantation was successful
Postoperative routine drug treatment
Traditional Chinese Medicine syndrome differentiation of qi -deficiency and qi -stagnation blood stasis or blood stasis license
Aged 35 to 75 years old
Must sign a consent form.
Exclusion Criteria:
Renal insufficiency, the male serum creatinine > 2.5 mg/dl (> 220 umo/l), women > 2.0 mg/dl (> 175 umo/l)
With obvious liver disease or Alanine aminotransferase ( ALT), Aspartate aminotransferase ( AST), 3 times higher than normal ceiling
Serious cardiac insufficiency (EF < 35%)
Uncontrolled patients with high blood pressure
Merger or severe valvular heart disease in acute cerebrovascular disease
Random blood glucose or greater tendency for 13.7 / L diabetes or glycosylated hemoglobin 9.5% or more
Patients with severe mental illness
Patients with malignant tumor or life expectancy in less than three years
Patients with severe hematopoietic system disease
Refused to sign a consent form, or estimated compliance is poorer, follow-up possibilities claim;
Pregnancy or ready to pregnant women, nursing mothers;
Participated in nearly three months, or is in other clinical subjects . -
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Huizheng Zhu, PHD
Phone
86-20-81887233
Ext
32808
Email
754357604@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Minzhou Zhang, MD
Organizational Affiliation
Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Huizheng Zhu, PhD
Organizational Affiliation
Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine
City
GuangZhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Minzhou Zhang, MD
Phone
86-20-81887233
Ext
32808
Email
1542377671@qq.com
First Name & Middle Initial & Last Name & Degree
Huizheng Zhu, PhD
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients
We'll reach out to this number within 24 hrs